Outline of clinical research
The following outline is provided as an overview of and topical guide to clinical research:
Clinical research is the aspect of biomedical research that addresses the assessment of new pharmaceutical and biological drugs, medical devices and vaccines in humans.
General topics
- Clinical significance – a conclusion that an intervention has an effect that is of practical meaning to patients
 - Drug discovery – the identification of candidates, synthesis, characterization, screening, and assays for therapeutic efficacy
 - Drug development – the process of taking a new chemical through the stages necessary to allow testing in clinical trials
 - Biotechnology – the technological application that uses biological systems, living organisms to make or modify products or processes for specific use
- Biopharmaceutical – a drug produced using biotechnology
 
 - Clinical trial – an experiment with human subjects to assess safety and efficacy of drugs
- Academic clinical trials – clinical trials run at academic centers (e.g., medical schools, academic hospitals, and universities)
 - Clinical trials unit – biomedical research units dedicated to conducting clinical trials
 
 - Epidemiology – the study of factors affecting the health and illness of populations
- Epidemiological methods – statistical techniques used in epidemiology
 
 - Evidence-based medicine – the assessment of the quality of evidence relevant to the risks and benefits of medical treatments
 - Pharmacology – the study of the interactions that occur between a living organism and drugs that alter normal biochemical function
- Biopharmacology – the pharmacology of biopharmaceuticals
 - Clinical pharmacology – the scientific discipline focused on rational drug development and utilization in therapeutics
 - Pharmacokinetics – the study of the fate of drugs administered to the body
- Bioequivalence – the biological equivalence of two preparations of a drug
 
 - Pharmacodynamics – the study of the biochemical and physiological effects of drugs on the body
 - Pharmacometrics – the science of interpreting and describing pharmacology in a quantitative fashion
 
 - Pharmacovigilance – the detection, assessment, understanding and prevention of adverse effects of medicines
 
Drug terminology
- Active ingredient – the substance in a drug that is pharmaceutically active
 - Approved drug – a drug that has been approved for marketing by a regulatory body such as the U.S. Food and Drug Administration or the European Medicines Agency
 - Excipient – an inactive substance used as a carrier for the active ingredients of a drug
 - Medicinal product – any substance or combination of substances used for treating or preventing disease in humans
 - Off-label use – the practice of prescribing a drug for an indication for which the drug has not been approved
 - Orphan drug – a drug used to treat a rare medical condition, or orphan disease
 - Placebo – a sham treatment given to a control group in a clinical study
 - Prescription drug – a licensed medicine that can only be obtained by prescription from a doctor
 - Standard treatment – a currently available drug used in an active control clinical study
 
Types of study design
- Blind experiment
 - Case report
 - Case series
 - Case study
 - Case-control study
 - Clinical control group
 - Cohort study
 - Cross-sectional study
 - Crossover study
 - First-in-man study
 - Longitudinal study
 - Minimisation
 - Multicenter trial
 - Nested case-control study
 - Observational study
 - Open-label trial
 - Placebo-controlled studies
 - Prospective cohort study
 - Randomized controlled trial
 - Retrospective cohort study
 - Run-in period
 - Seeding trial
 - Vaccine trial
 
Study participant confidentiality and safety
- Adverse drug reaction
 - Adverse event
 - Council for International Organizations of Medical Sciences
 - Data confidentiality in clinical trials
 - Data monitoring committees
 - Ethics Committee (European Union)
 - EudraVigilance
 - Exclusion criteria
 - Great ape research ban
 - Inclusion criteria
 - Institutional review board
 - MedWatch
 - Safety monitoring
 - Serious adverse event
 - Suspected Adverse Reaction Surveillance Scheme
 
Clinical study management
Clinical research documents
- Clinical trial protocol
 - Informed consent
 - Investigator's brochure
 - Source document
 - Standing operating procedure
 
Clinical research personnel
Contract research organizations
Contract research organization
Data collection and management
- Case report form
 - Clinical data management system
 - Clinical data repository
 - Data clarification form
 - Electronic data capture
 - Good clinical data management practice
 - Patient diary
 - Patient-reported outcome
 - Remote data entry
 
Medical term coding dictionaries
- Uppsala Monitoring Centre
 - COSTART
 - MedDRA
 - Systematized Nomenclature of Medicine (SNOMED)
 - WHOART
 - Common Terminology Criteria for Adverse Events
 
Clinical Data Interchange Standards Consortium
Clinical Data Interchange Standards Consortium
- Study Data Tabulation Model (SDTM)
 - Standard for Exchange of Non-clinical Data (SEND)
 - JANUS clinical trial data repository
 
Data analysis
- Censoring (clinical trials)
 - Effect size
 - End point of clinical trials
 - Hazard ratio
 - Meta-analysis
 - Number needed to harm
 - Number needed to treat
 - Odds ratio
 - Intention to treat analysis
 - Post-hoc analysis
 - Relative risk
 - Risk–benefit analysis
 - Sensitivity and specificity
 - Subgroup analysis
 - Substantial equivalence
 - Surrogate endpoint
 - Systematic review
 - Therapeutic effect
 
Results reporting
- Medical writing
 - Clinical trials publication
 - Common Technical Document
 - Consolidated Standards of Reporting Trials (CONSORT)
 - Electronic Common Technical Document
 - Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
 - Strengthening the reporting of observational studies in epidemiology (STROBE)
 - Uniform Requirements for Manuscripts Submitted to Biomedical Journals (URM)
 
Notable clinical studies
- British Doctors Study – in 1956 provided convincing statistical proof that tobacco smoking increased the risk of lung cancer.
 - Framingham Heart Study – a cardiovascular study based in Framingham, Massachusetts, which began in 1948 with 5,209, and is now on its third generation of participants.
 - Heart Protection Study – the largest study to investigate the use of statins in the prevention of cardiovascular disease.
 - International Studies of Infarct Survival – four randomized controlled trials of several drugs for treating suspected acute myocardial infarction.
 - Intersalt study – a landmark observational study that showed a strong association between dietary salt and risk of cardiovascular disease.
 - JUPITER trial – the first clinical trial to demonstrate that statin therapy may provide benefit to patients with low-to-normal LDL levels and no known cardiovascular disease.
 - Multicenter AIDS Cohort Study – a study of over 6,000 men infected with HIV that has been ongoing for over 25 years
 - Stateville Penitentiary Malaria Study – a controlled study of the effects of malaria on the inmates of Stateville Penitentiary near Joliet, Illinois.
 - Tuskegee Study of Untreated Syphilis in the Negro Male – a clinical study, conducted between 1932 and 1972 in Tuskegee, Alabama studied the natural progression of the disease if left untreated.
 
Legislation, regulations and guidances
| Regulation of therapeutic goods in the United States | 
|---|
![]()  | 
| 
Prescription drugs Over-the-counter drugs  | 
European Union
- Directive 2001/20/EC
 - Directive 2001/83/EC
 - Directive 2005/28/EC
 - Directive 65/65/EEC
 - Directive 93/41/EEC
 - Directive 95/46/EC on the protection of personal data
 
United States
- Federal Food, Drug, and Cosmetic Act (FD&C) – gives authority to the Food and Drug Administration (FDA) to oversee the safety of food, drugs, and cosmetics.
- Kefauver Harris Amendment – requires drug manufacturers to provide proof of the effectiveness and safety of drugs before approval.
 
 - Prescription Drug User Fee Act – allows the Food and Drug Administration (FDA) to collect fees from drug manufacturers to fund the new drug approval process.
 - Title 21 of the Code of Federal Regulations – the section of Federal regulations that interprets and enforces FD&C.
 - Title 21 CFR Part 11 – defines the criteria under which electronic records and electronic signatures are considered to be trustworthy, reliable and equivalent to paper records.
 - Health Insurance Portability and Accountability Act (HIPAA) – Title II of HIPAA addresses the security and privacy of health data, including data collected from subjects in clinical research.
 
Other
- Declaration of Helsinki (United Nations)
 - Food and Drugs Act (Canada)
 - International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (European Union, Japan, and United States)
 
Government agencies
- Australian Drug Evaluation Committee
 - European Medicines Agency
 - Federal Agency for Medicines and Health Products (Belgium)
 - Medicines and Healthcare products Regulatory Agency (United Kingdom)
 - Ministry of Health, Labour and Welfare (Japan)
 - Norwegian Medicines Agency
 - State Food and Drug Administration (China)
 - Swedish Medical Products Agency
 - Therapeutic Products Directorate (Canada)
 - Therapeutic Goods Administration (Australia)
 
United States Food and Drug Administration
Departments
- Commissioner of Food and Drugs – as head of the Food and Drug Administration, the commissioner reports to the Secretary of the Department of Health and Human Services
 - Center for Biologics Evaluation and Research – responsible for review and approval of biologic products, including vaccines, blood products, gene therapy and human cloning
 - Center for Devices and Radiological Health – responsible for review and approval of medical devices and safety of non-medical equipment that emit certain types of radiation
 - Center for Drug Evaluation and Research – responsible for review and approval of all drugs
 - Office of Regulatory Affairs – enforces FDA laws and regulations
 
Review and approval programs
- Investigational Device Exemption – allows an investigational device to be used in a clinical study in order to collect safety and effectiveness data
 - Investigational New Drug – allows an investigational drug to be used in a clinical study in order to collect safety and effectiveness data
 - New Drug Application – a submission to the FDA by a pharmaceutical company for review and approval of a new drug
- Abbreviated New Drug Application – a submission to the FDA review and approval of a generic drug
 - FDA Fast Track Development Program – a designation given to an NDA by the FDA that accelerates review and approval of new drugs
 
 
